<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04754581</url>
  </required_header>
  <id_info>
    <org_study_id>1581803</org_study_id>
    <nct_id>NCT04754581</nct_id>
  </id_info>
  <brief_title>Dynamic in Vivo PET Imaging and ex Vivo Biopsies From Skeletal Muscle and Adipose Tissue to Investigate the Effects of Exercise on Insulin Resistance and Mitochondrial Energetics in Type 2 Diabetes</brief_title>
  <acronym>EXPET</acronym>
  <official_title>Dynamic in Vivo PET Imaging and ex Vivo Biopsies From Skeletal Muscle and Adipose Tissue to Investigate the Effects of Exercise on Insulin Resistance and Mitochondrial Energetics in Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Translational Research Institute for Metabolism and Diabetes, Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Translational Research Institute for Metabolism and Diabetes, Florida</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall aim of this pilot study is to investigate the effects of exercise training on&#xD;
      skeletal muscle and adipose tissue insulin resistance in subjects with Type 2 Diabetes (T2D).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 30, 2021</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is a single-site, pre-post design pilot study with no control group.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Individual steps of muscle glucose uptake (pre-exercise)</measure>
    <time_frame>24 hours</time_frame>
    <description>Muscle glucose uptake will be assessed two times (pre and post exercise intervention) on the biceps femoris and vastus lateralis through PET imaging and hyperinsulinemic euglycemic clamp.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Individual steps of muscle glucose uptake (post-exercise)</measure>
    <time_frame>24 hours</time_frame>
    <description>Muscle glucose uptake will be assessed two times (pre and post exercise intervention) on the biceps femoris and vastus lateralis through PET imaging and hyperinsulinemic euglycemic clamp.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>All Participants</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Maximal ATP Production (ATPmax)</intervention_name>
    <description>ATPmax will be measured in order to determine in vivo mitochondrial capacity. The magnetic resonance scans to measure mitochondrial energetics will also be performed.</description>
    <arm_group_label>All Participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Exercise Testing (VO2max)</intervention_name>
    <description>Aerobic fitness level will be assessed while participant pedals on a stationary bicycle/walk on a treadmill. The volume of oxygen intake and carbon dioxide (CO2) production will be measured.</description>
    <arm_group_label>All Participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Muscle Biopsy</intervention_name>
    <description>Sample muscle cells from the left leg Vastus Lateralis (thigh) muscle.</description>
    <arm_group_label>All Participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Adipose Tissue Biopsy</intervention_name>
    <description>Sample fat tissue from the abdomen.</description>
    <arm_group_label>All Participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hyperinsulinemic euglycemic clamp</intervention_name>
    <description>Measurement of insulin sensitivity.</description>
    <arm_group_label>All Participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PET imaging</intervention_name>
    <description>After an overnight fast, an intravenous catheter will be placed in each arm (one with arterial line for PET infusion, and the other for infusion of insulin, glucose, and 6,6 D2 glucose tracer. FDG-glucose will be injected followed by 90-minute PET scanning of the thigh.</description>
    <arm_group_label>All Participants</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 30-65 years&#xD;
&#xD;
          2. Men and women&#xD;
&#xD;
          3. Body mass index (BMI) between 25 and 45 kg/m2&#xD;
&#xD;
          4. Sedentary (1 day or less per week of structured exercise)&#xD;
&#xD;
          5. Type 2 diabetes mellitus determined by self-report or by a fasting glucose &gt;126mg/dl&#xD;
&#xD;
          6. Weight stable (± 2 kg) for prior 3 months&#xD;
&#xD;
          7. Willing to commit to the schedule of assessment visits, including the exercise&#xD;
             intervention&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Currently taking insulin, injectable incretin mimetics and thiazolidinediones&#xD;
&#xD;
          2. Taking more than two glucose-lowering medications&#xD;
&#xD;
          3. Resting blood pressure ≥ 160/100 mm Hg&#xD;
&#xD;
          4. Triglycerides ≥ 500 mg/dL&#xD;
&#xD;
          5. Any renal, cardiac, liver, lung, or neurological disease that in the opinion of the&#xD;
             principal investigator would compromise participant safety or the participants'&#xD;
             ability to complete the exercise training protocol&#xD;
&#xD;
          6. Any significant disease or unstable medical condition (i.e., coronary heart disease,&#xD;
             chronic renal failure, chronic hepatic disease, severe pulmonary disease)&#xD;
&#xD;
          7. Presence of clinically significant abnormalities on electrocardiogram (ECG) that is a&#xD;
             contra-indication to exercise training&#xD;
&#xD;
          8. Pulse check (&quot;Allen test&quot;) indicates participant has poor blood flow in the hands&#xD;
&#xD;
          9. Cancer (active malignancy with or without concurrent chemotherapy; except for basal&#xD;
             cell carcinoma)&#xD;
&#xD;
         10. Pregnancy during the previous 6 months, lactating, or planned pregnancy in the next&#xD;
             year&#xD;
&#xD;
         11. Use of drugs known to affect energy metabolism or body weight: including, but not&#xD;
             limited to orlistat, sibutramine, ephedrine, phenylpropanolamine, corticosterone, etc&#xD;
&#xD;
         12. Current treatment with blood thinners or anti-platelet medications that cannot be&#xD;
             safely stopped for testing procedures&#xD;
&#xD;
         13. Participant is currently taking anti-inflammatory medication or has had inflammatory&#xD;
             medication within 1 week prior to screening (including over the counter formulations:&#xD;
             e.g. Aleve, Motrin, Ibuprofen, Naproxen, low dose ASA.&#xD;
&#xD;
         14. New onset (&lt;3 months on a stable regime) hormone replacement therapy&#xD;
&#xD;
         15. Current use of beta-adrenergic blocking agents&#xD;
&#xD;
         16. Major surgery on the abdomen, pelvis, or lower extremities within previous 3 months&#xD;
&#xD;
         17. Increased liver function tests (AST/ALT/GGT/or alkaline phosphatase greater than 2.5&#xD;
             times the upper limit of normal)&#xD;
&#xD;
         18. Abnormal blood count/anemia, blood transfusion or blood donation within the last 2&#xD;
             months&#xD;
&#xD;
         19. Current smokers (smoking within the past 3 months prior to screening visit, including&#xD;
             any/all tobacco products)&#xD;
&#xD;
         20. Current drug or alcohol abuse/dependence&#xD;
&#xD;
         21. Metal implants (pace-maker, aneurysm clips) based on investigator's judgment at&#xD;
             screening&#xD;
&#xD;
         22. Not physically capable of performing the exercise required of the study protocols&#xD;
&#xD;
         23. Plans to be away &gt;2 weeks in the next 3 months&#xD;
&#xD;
         24. Unable to participate in Magnetic Resonance Imaging (MRI) assessments due to physical&#xD;
             limitations of equipment tolerances (e.g. MRI bore size) based on investigator's&#xD;
             judgment at screening.&#xD;
&#xD;
         25. Unable to tolerate MRI or claustrophobia.&#xD;
&#xD;
         26. Nickel allergy&#xD;
&#xD;
         27. Lidocaine allergy&#xD;
&#xD;
         28. Unable or unwilling to communicate with staff or to provide written informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bret Goodpaster, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Scientific Director | Senior Investigator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruitment Department</last_name>
    <phone>407-303-7100</phone>
    <email>Fh.tri.recruitment@adventhealth.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>AdventHealth Translational Research Institute</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Recruitment Department</last_name>
      <phone>407-303-7100</phone>
      <email>Fh.tri.recruitment@adventhealth.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.adventhealthresearchinstitute.com/research/translational-research</url>
    <description>Website for AdventHealth Translational Research Institute</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 5, 2021</study_first_submitted>
  <study_first_submitted_qc>February 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2021</study_first_posted>
  <last_update_submitted>May 10, 2021</last_update_submitted>
  <last_update_submitted_qc>May 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

